Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 27, 2008.
Business Overview: Greatbatch is a developer and manufacturer of critical products for medical devices (cardiac rhythm management, neuromodulation, orthopedics) and electrochemical cells/batteries for industrial and military applications. The company operates two segments: Implantable Medical Components (IMC) and Electrochem.
Key Financial Metrics
| Metric (in thousands) | Q2 2008 | Q2 2007 | 6 Months 2008 | 6 Months 2007 |
|---|---|---|---|---|
| Sales | $141,648 | $78,462 | $263,802 | $155,322 |
| Operating Income | $11,352 | $(6,351) | $7,212 | $4,255 |
| Net Income | $5,805 | $(3,399) | $2,431 | $7,270 |
| Diluted EPS | $0.25 | $(0.15) | $0.11 | $0.33 |
| Operating Margin | 8.0% | -8.1% | 2.7% | 2.7% |
| Cash & Equivalents | $20,011 | $33,473 (Dec 2007) | N/A | |
| Short-term Investments | $1,558 | $7,017 (Dec 2007) | N/A | |
| Total Debt (Long-term + Current) | $357,943 | $241,198 (Dec 2007) | N/A | |
| Working Capital | $126,953 | $116,816 (Dec 2007) | N/A |
Note: Debt figures include $114 million in revolving credit facility borrowings and $241.9 million in convertible subordinated notes.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 81% year-over-year in Q2 2008, driven primarily by acquisitions (Precimed and Chaumont Facility) contributing $64.2 million. Excluding acquisitions, organic sales grew 1%.
- Profitability Turnaround: Operating income improved from a loss of $6.4 million in Q2 2007 to a profit of $11.4 million in Q2 2008. This was aided by a significant reduction in acquisition-related charges (from $20.5 million in Q2 2007 to $2.9 million in Q2 2008).
- Segment Performance:
- IMC Segment: Sales rose 80% to $121.5 million, with the new Orthopedic line contributing $41.0 million. CRM/Neuromodulation sales declined 2% due to lower demand for coated components and ICD batteries.
- Electrochem Segment: Sales increased 85% to $20.1 million, driven by the EAC acquisition and higher demand in the oil and gas market.
- Cost Structure: Cost of sales as a percentage of sales increased to 71.3% (from 59.6% in 2007) due to lower margins in acquired businesses and inventory step-up amortization in the prior year. However, SG&A as a percentage of sales decreased slightly to 13.2%.
- Debt Levels: Long-term debt increased significantly due to $117 million borrowed under the revolving credit facility to fund the Precimed and Chaumont Facility acquisitions.
Guidance, Outlook, Risks, and Unusual Items
- Acquisition Integration: Management expects it will take approximately two years to fully implement consolidation and "Lean" manufacturing initiatives to improve operating profitability. Integration costs are expected to continue into the first half of 2009.
- Capital Expenditures: Expected capital spending for the remainder of 2008 is estimated at $30 million to $35 million, primarily for the new Electrochem facility and corporate office expansion.
- Tax Outlook: The effective tax rate for 2008 is expected to be approximately 37%. A Swiss tax holiday granted in Q2 2008 reduced deferred tax liabilities by $0.9 million.
- Unusual Items:
- IPR&D Charges: $2.2 million of in-process research and development (IPR&D) from the Precimed acquisition was expensed in Q1 2008. No IPR&D charges were recorded in Q2 2008.
- Foreign Currency Gain: A $2.4 million gain on foreign currency contracts was realized in Q1 2008 related to funding acquisitions in Swiss Francs and Euros.
- Risks and Contingencies:
- Patent Litigation: A jury found Enpath (a Greatbatch subsidiary) liable for patent infringement regarding FlowGuard™ valved introducers, awarding $1.1 million in damages. The court enjoined sales of the ViaSeal™ prototype but permitted FlowGuard™ sales pending appeal if a royalty of $1.50–$2.25 per unit is paid into escrow. Greatbatch intends to appeal.
- Customer Concentration: Four customers accounted for 56% of total sales in Q2 2008 (down from 69% in Q2 2007).
- Raw Materials: Prices for critical raw materials (including precious metals) have increased significantly, though supply agreements allow for partial price adjustments.
Key Facts for Investor Verification
- Acquisition Valuation: Verify the final purchase price allocation for the Precimed and Chaumont Facility acquisitions, as preliminary valuations for goodwill and intangible assets are subject to adjustment within 12 months.
- Debt Covenants: Confirm compliance with credit facility covenants, specifically the adjusted EBITDA to interest expense ratio (minimum 3.00:1) and total leverage ratio (maximum 5.00:1 through Sept 2009).
- Litigation Outcome: Monitor the appeal process regarding the Pressure Products patent infringement case, as an unfavorable final ruling could impact future sales of FlowGuard™ products.
- Integration Costs: Track the realization of cost savings from consolidation initiatives against the projected $4.1 million to $5.3 million total cost for 2007/2008 facility shutdowns.
- Convertible Notes: Review the impact of FSP APB 14-1 (effective 2009) on the accounting for $198 million of convertible debt with cash settlement features, which may increase reported interest expense.